Equities analysts expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to announce sales of $95.62 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Ironwood Pharmaceuticals' earnings. The highest sales estimate is $97.73 million and the lowest is $93.50 million. Ironwood Pharmaceuticals posted sales of $89.43 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.9%. The company is scheduled to issue its next earnings results before the market opens on Thursday, August 5th.
On average, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $401.74 million for the current financial year, with estimates ranging from $383.26 million to $415.66 million. For the next fiscal year, analysts expect that the business will post sales of $434.81 million, with estimates ranging from $420.70 million to $460.35 million. Zacks Investment Research's sales calculations are an average based on a survey of sell-side research firms that follow Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, May 6th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.02. Ironwood Pharmaceuticals had a net margin of 35.83% and a return on equity of 447.47%. The business had revenue of $88.80 million during the quarter, compared to analysts' expectations of $87.94 million. During the same period last year, the business earned $0.04 earnings per share. The firm's revenue was up 11.1% on a year-over-year basis.
IRWD has been the subject of several analyst reports. Northland Securities reissued a "buy" rating and issued a $15.00 target price on shares of Ironwood Pharmaceuticals in a research note on Tuesday, July 6th. Morgan Stanley lifted their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock an "equal weight" rating in a research report on Friday, July 16th. Finally, Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a "sell" rating to a "buy" rating and set a $11.00 price objective for the company in a research report on Tuesday, April 20th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. The stock currently has a consensus rating of "Hold" and a consensus price target of $11.80.
NASDAQ:IRWD opened at $13.02 on Friday. Ironwood Pharmaceuticals has a 1-year low of $8.63 and a 1-year high of $13.34. The company has a quick ratio of 22.80, a current ratio of 22.80 and a debt-to-equity ratio of 3.96. The firm has a fifty day moving average price of $12.21. The company has a market capitalization of $2.11 billion, a PE ratio of 14.63 and a beta of 1.39.
In other news, CMO Michael Shetzline sold 2,077 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, May 24th. The stock was sold at an average price of $12.25, for a total transaction of $25,443.25. Following the completion of the sale, the chief marketing officer now owns 197,437 shares of the company's stock, valued at $2,418,603.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark G. Currie sold 23,571 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, June 14th. The stock was sold at an average price of $11.59, for a total value of $273,187.89. Following the sale, the director now directly owns 570,187 shares of the company's stock, valued at approximately $6,608,467.33. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,880 shares of company stock valued at $325,973. Company insiders own 12.60% of the company's stock.
A number of hedge funds have recently bought and sold shares of the stock. Sarissa Capital Management LP raised its stake in Ironwood Pharmaceuticals by 16.7% in the first quarter. Sarissa Capital Management LP now owns 16,390,000 shares of the biotechnology company's stock valued at $183,240,000 after purchasing an additional 2,350,000 shares in the last quarter. BlackRock Inc. raised its stake in Ironwood Pharmaceuticals by 2.3% in the first quarter. BlackRock Inc. now owns 13,348,564 shares of the biotechnology company's stock valued at $149,239,000 after purchasing an additional 303,914 shares in the last quarter. Renaissance Technologies LLC raised its stake in Ironwood Pharmaceuticals by 56.6% in the first quarter. Renaissance Technologies LLC now owns 3,140,753 shares of the biotechnology company's stock valued at $35,114,000 after purchasing an additional 1,135,000 shares in the last quarter. Bridger Management LLC raised its stake in Ironwood Pharmaceuticals by 15.6% in the first quarter. Bridger Management LLC now owns 2,852,414 shares of the biotechnology company's stock valued at $31,890,000 after purchasing an additional 385,442 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Ironwood Pharmaceuticals by 12.2% in the first quarter. Geode Capital Management LLC now owns 2,776,343 shares of the biotechnology company's stock valued at $31,039,000 after purchasing an additional 302,099 shares in the last quarter.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
See Also: Federal Reserve
Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Ironwood Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.
While Ironwood Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here